PT  - JOURNAL ARTICLE
AU  - Omori, Ryosuke
AU  - Mizumoto, Kenji
AU  - Nishiura, Hiroshi
TI  - Ascertainment rate of novel coronavirus disease (COVID-19) in Japan
AID  - 10.1101/2020.03.09.20033183
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.09.20033183
4099  - http://medrxiv.org/content/early/2020/03/10/2020.03.09.20033183.short
4100  - http://medrxiv.org/content/early/2020/03/10/2020.03.09.20033183.full
AB  - Objective To estimate the ascertainment rate of novel coronavirus (COVID-19).Methods We analyzed the epidemiological dataset of confirmed cases with COVID-19 in Japan as of 28 February 2020. A statistical model was constructed to describe the heterogeneity of reporting rate by age and severity. We estimated the number of severe and non-severe cases, accounting for under-ascertainment.Results The ascertainment rate of non-severe cases was estimated at 0.44 (95% confidence interval: 0.37, 0.50), indicating that unbiased number of non-cases would be more than twice the reported count.Conclusions Severe cases are twice more likely diagnosed and reported than other cases. Considering that reported cases are usually dominated by non-severe cases, the adjusted total number of cases is also about a double of observed count. Our finding is critical in interpreting the reported data, and it is advised to interpret mild case data of COVID-19 as always under-ascertained.Highlights- Epidemiological dataset of COVID-19 in Japan was analyzed.- The ascertainment rate of non-severe cases was estimated at 0.44 (95% confidence interval: 0.37, 0.50).- Severe cases are twice more likely diagnosed and reported than other cases.- Mild cases of COVID-19 are under-ascertained.Competing Interest StatementThe authors have declared no competing interest.Funding StatementH.N. received funding support from Japan Agency for Medical Research and Development [grant number: JP18fk0108050] the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI in Japanese abbreviation) grant nos. 17H04701, 17H05808, 18H04895 and 19H01074, and the Japan Science and Technology Agency (JST) Core Research for Evolutional Science and Technology (CREST) program [grant number: JPMJCR1413]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.